Journal of Hematology and Oncology
Journal of Hematology and Oncology is a journal indexed in SJR in Molecular Biology and Hematology with an H index of 171. It is an CC BY Journal with a Single blind Peer Review review system, and It has a price of 1815 €. The scope of the journal is focused on haematology, oncology. It has a COP Index of 27,4 (best band D1). It is published in English. It has a COP Index of 27,4.
Journal of Hematology and Oncology focuses its scope in these topics and keywords: biomarkers, lymphoma, pathways, lymphoid, leukemia, natural, myeloid, biology, tumors, killer, ...
2 of 119 journals in Hematology
Metrics
Scimago and CountryOfPapers database fields
COP Index
27,4
D1 Top 10%
SJR Impact
10,192
H-index
171
Docs (year)
125
Docs 3y
482
Total refs
14265
Cites 3y
12770
Citable 3y
334
Cites/Doc 2y
26.08
Ref/Doc
114.12
Immediate OA
1815 €
Embargoed OA
NPD
Non OA / Submission
- €
Name good journals. Call out predatory ones.
Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.
Researcher reviews
Best articles by citations
Ferroptosis, a new form of cell death: opportunities and challenges in cancer
Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications
The biology and role of CD44 in cancer progression: therapeutic implications
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity
Nanomaterials for cancer therapy: current progress and perspectives
Tumor-associated macrophages: from basic research to clinical application
Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers
Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma
SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Wnt/beta-catenin pathway: modulating anticancer immune response
Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
Role of platelets and platelet receptors in cancer metastasis
The interplay between m6A RNA methylation and noncoding RNA in cancer
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
NK cell-based cancer immunotherapy: from basic biology to clinical development
Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development